Physician profile
Michael J Moutsatson
NPI 1669583332
$2,600.93
in general payments reported to CMS, 2019-2025
11 companies · $2,226 in 2025
The $2,226 reported for 2025 was more than what a typical Orthopaedic Surgery provider received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $101 · 2021: $30.95 · 2022: $48.05 · 2024: $196 · 2025: $2,226.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,729 · Food and Beverage: $692.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,729.23 |
| Food and Beverage | $692.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arthrex, INC. | $1,069.90 | 2025 | |
| Zak Ortho | $997.55 | 2025 | |
| Depuy Synthes Sales INC. | $329.62 | 2019-2025 | Velys, Orthovisc, Monovisc |
| Orthofix Medical, INC. | $42.48 | 2021-2024 | Physio-Stim |
| Sanofi-Aventis U.S. LLC | $41.18 | 2019-2022 | |
| Bioventus LLC | $40.32 | 2021-2025 | Durolane |
| Medtronic USA, INC. | $21.26 | 2019 | |
| Ferring Pharmaceuticals INC. | $15.56 | 2019 | |
| Embody, INC. | $15.27 | 2022 | |
| Pacira Therapeutics, INC. | $13.93 | 2019 | |
| Zimmer Biomet Holdings, INC. | $13.86 | 2024 | Persona |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Moutsatson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.